{
  "guideline": {
    "id": "PA166182739",
    "name": "Annotation of FDA Label for tafenoquine and G6PD",
    "source": "FDA",
    "version": 11,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182739",
    "relatedChemicals": [
      {
        "id": "PA166115580",
        "name": "tafenoquine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA28469",
        "name": "glucose-6-phosphate dehydrogenase",
        "symbol": "G6PD"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166315081",
      "name": "Recommendation Annotation PA166315081",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166115580",
          "name": "tafenoquine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452245620,
        "html": "<p>&quot;ARAKODA [tafenoquine] is contraindicated in: patients with G6PD deficiency or unknown G6PD status due to the risk of hemolytic anemia...[and] breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if the G6PD status of the infant is unknown...&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Variable"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312291",
      "name": "Recommendation Annotation PA166312291",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166115580",
          "name": "tafenoquine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216552,
        "html": "<p>&quot;ARAKODA [tafenoquine] is contraindicated in: patients with G6PD deficiency or unknown G6PD status due to the risk of hemolytic anemia...[and] breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if the G6PD status of the infant is unknown...&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient with CNSHA"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312292",
      "name": "Recommendation Annotation PA166312292",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166115580",
          "name": "tafenoquine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216553,
        "html": "<p>&quot;ARAKODA [tafenoquine] is contraindicated in: patients with G6PD deficiency or unknown G6PD status due to the risk of hemolytic anemia...[and] breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if the G6PD status of the infant is unknown...&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Arakoda (Tafenoquine), NDA210607, 60 Degrees Pharmaceuticals, LLC",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210607"
    }
  ],
  "version": "2024-02-29-20-19"
}